35 results
8-K
EX-99.1
818wddzrpogxy3fvzy06
1 Dec 20
Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint
5:19pm
8-K
EX-99.1
kdt1l1anxc o84riscg
22 Oct 20
Regulation FD Disclosure
1:14pm
8-K
EX-99.1
8veircv
13 Mar 20
Regulation FD Disclosure
9:06am
8-K
EX-99.1
c5z09xm 81u4
2 Mar 20
Regulation FD Disclosure
3:48pm
424B5
jws i0el7
7 Oct 19
Prospectus supplement for primary offering
9:35pm
424B5
emxabafhz6f
7 Oct 19
Prospectus supplement for primary offering
9:33pm
424B5
fc3ko5h9
3 Oct 19
Prospectus supplement for primary offering
4:11pm
424B5
wr8tqkw
3 Oct 19
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
8ufx1
12 Sep 19
Ovid Therapeutics Announces First Patient Randomized in Pivotal Phase 3 NEPTUNE Trial of OV101 for the Treatment of Angelman Syndrome
8:10am
8-K
EX-99.1
ufs8by6v4l pg9ah
9 Sep 19
Other Events
12:00am
8-K
EX-99.1
yn4n8t90 mxn4o4
27 Jun 19
Regulation FD Disclosure
12:04pm
8-K
EX-99.1
dg02hm0w1mp553wg t3d
27 Jun 19
Other Events
8:05am